Expanded Access Policy
Our purpose at Actio Biosciences, Inc. is to develop new therapies that have a positive impact on patient health, and to serve patients, patient families and patient communities through education, empathy, and awareness.
We are united by a shared commitment to advancing science with purpose, aiming to turn new insights into therapies that can genuinely improve patients’ lives. We move with both urgency and care, recognizing the responsibility we carry to deliver progress. Every step forward matters, especially as patients continue to wait for safer, more effective treatment options.
Actio Biosciences is committed to making investigational drug ABS-1230 available to seriously ill patients with a life-threatening condition who will not be eligible for our clinical trials and do not have options for alternative therapies. In these unique circumstances, Actio Biosciences may consider expanded access requests, also known as compassionate use or managed access, from a treating healthcare provider (HCP) for an individual patient. Requests will be considered on a case-by-case basis. For a request to be considered, both the patient eligibility criteria and HCP responsibilities described below must be met. All requests must be submitted by the patient’s treating HCP and cannot be accepted from patients or family members.
Criteria Evaluated by Actio Biosciences
Actio Biosciences will evaluate whether:
- The patient is under 2 years of age, in or recently in an intensive care unit for KCNT1-related epilepsy with an identified pathogenic or likely pathogenic mutation, having a high seizure burden, and whose condition is refractory to available treatment options;
- The patient is located in a region where ABS-1230 clinical trial activities are not ongoing or planned; but an expanded access patient could be supported.
- Based on the severity of the patient, exceptions for the region criterion may be considered on a case-by-case basis if the patient is not eligible for an ongoing clinical trial or planned clinical trial, provided all other expanded access criteria are met. All reasonable efforts should be made to include potentially eligible patients in clinical studies before considering expanded access.
- Based on the available clinical and nonclinical data, the potential benefits of treatment with ABS-1230 outweigh the potential risks for the individual patient; and
- Providing access to investigational drug ABS-1230 will not negatively impact or delay the ongoing clinical trials or regulatory review or approval of ABS-1230.
Responsibilities of the Treating Healthcare Provider
The treating healthcare provider must:
- Confirm the patient is under 2 years of age, in or recently in an intensive care unit for KCNT1-related epilepsy with an identified pathogenic or likely pathogenic mutation, having a high seizure burden, and whose condition is refractory to available treatment options.
- Provide sufficient clinical information to allow Actio Biosciences to evaluate the request, including the patient’s medical history, pathogenic mutation, prior treatment experience, and current condition, weight, and medications, and if the patient has a feeding tube and/or is on a ketogenic diet.
- Adhere to and agree to oversee the proper administration of ABS-1230 and provide appropriate patient care, monitoring, and follow-up.
- Obtain all required regulatory, ethics committee, and institutional approvals before treatment is initiated. Or in cases where Actio is the regulatory Sponsor, provide sufficient and timely information as required by the regulatory authorities or participate in meetings with regulatory agencies related to the EAP request.
- Obtain informed consent from the patient’s parent(s) or legal guardian(s), as applicable.
- Comply with all applicable safety reporting, monitoring, drug accountability, and regulatory requirements associated with Expanded Access treatment.
- Identify and provide the address for a suitable Importer of Record, if not in the United States.
Actio Biosciences continually evaluates the benefit-risk profile of each of our investigational drugs as new clinical data becomes available. Because each patient’s circumstances are unique, the availability of ABS-1230 for one patient does not guarantee the availability for another patient whose circumstances and medical histories may be different.
Actio Biosciences is committed to evaluating all requests in a fair and equitable manner. We may require more detailed information in order to fully evaluate a request. Each request will be given careful consideration by Actio Biosciences whose decisions are final.
Expanded Access Policy dated: October 19, 2026